AZD 1175

Drug Profile

AZD 1175

Alternative Names: AZD1175

Latest Information Update: 27 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 29 Jan 2009 Discontinued - Phase-I for Obesity in Europe (unspecified route)
  • 29 Jan 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in Europe (unspecified route)
  • 01 Feb 2007 Phase-I clinical trials in Obesity in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top